AU2001262257A1 - Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists - Google Patents
Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonistsInfo
- Publication number
- AU2001262257A1 AU2001262257A1 AU2001262257A AU2001262257A AU2001262257A1 AU 2001262257 A1 AU2001262257 A1 AU 2001262257A1 AU 2001262257 A AU2001262257 A AU 2001262257A AU 2001262257 A AU2001262257 A AU 2001262257A AU 2001262257 A1 AU2001262257 A1 AU 2001262257A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- acid addition
- free base
- addition salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
The present invention relates to novel azabicyclic carbamates, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
More particularly the invention provides a compound of formula I
wherein n is 1 or 2, Ri, R2 and R3, independently, are hydrogen or (C1-4)alkyl and A is a group of formula
wherein m is 1, 2 or 3, X is O, S, NH or CH2 and R4 and R5, independently, are hydrogen, halogen, hydroxy, (C1.4)alkyl, (C1-4)alkoxy, (C!.4)alkylthio, (Cι.4)alkylamino, nitro, trifluoromethyl or phenyl, in free base or acid addition salt form.
Halogen denotes fluorine, bromine, chlorine or iodine.
Any alkyl, alkoxy and alkylthio groups are branched or straight chain groups. They are preferably methyl, methoxy or methylthio groups.
On account of the asymmetrical carbon atom(s) present in the compounds of formula I and their salts, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures. All optical isomers and their mixtures including the racemic mixtures are part of the present invention.
In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, comprising the step of reacting a compound of formula II
wherein n, Ri and R2 are as defined above, with a compound of formula HI
wherein R and A are as defined above, and N, N'-carbonyldiimidazole or di(N- succinimidyl)carbonate, and recovering the resulting compound of formula I in free base or acid addition salt form.
According to a preferred embodiment, in a first step the compound of formula III is reacted with N, N'-carbonyldiimidazole, and the resulting compound is reacted with the compound of formula II.
Alternatively, the compound of formula II can be reacted with a compound of formula rv
wherein R and A are as defined above.
The reactions can be effected according to conventional methods, e.g. as described in the examples.
Working up the reaction mixtures according to the above processes and purification of the compounds thus obtained may be carried out in accordance to known procedures.
Acid addition salts may be produced from the free bases in known manner, and vice versa.
Compounds of formula I in optically pure form can be obtained from the corresponding racemates according to well-known procedures. Alternatively, optically pure starting materials can be used.
The starting materials of formula II, m and IV are known or may be obtained from known compounds, using conventional procedures.
Compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.
In particular, the agents of the invention are α7 nicotinic acetylcholine receptor (nAChR) agonists.
In functional assays, the agents of the invention display high affinity at the α7 nAChR as shown in the following tests:
a) A functional assay for affinity at human α7 nAChR is carried out with a rat pituitary cell line stably expressing the human α7 nAChR. As a read out, the calcium influx upon stimulation of the receptor is used. In this assay, agents of the invention exhibit pECso values of about 5 to about 8.
b) To assess the activity of the agents of the invention on the human neuronal nAChR α4β2, a similar functional assay is carried out using a human epithelial cell line stable expressing the human α4β2 subtype. In this assay, agents of the invention show selectivity for the α7 nAChR subtypes.
c) To assess the activity of the compounds of the invention on the "ganglionic subtype" and the muscle type of nicotinic receptor, similar functional assays as described under a) are carried out with a human epithelial cell line stably
expressing the human ganglionic subtype or a cell line endogenously expressing the human muscle type of nicotinic receptors. In these assays, agents of the invention display no or little activity on the ganglionic and muscle type of nicotinic receptor subtypes.
In the model of mice showing sensory gating deficit (DBA/2 -mice) described by S. Leonard et al. in Schizophrenia Bulletin 22, 431-445 (1996), the agents of the invention induce significant sensory gating at concentrations of about 10 to about 40 μM.
The agents of the invention are therefore useful for the treatment of psychotic disorders such as schizophrenia, mania, depression and anxiety, and for the treatment of neurodegenerative disorders such as senile dementia, Alzheimer's disease and other intellectual impairment disorders, such as attention deficit hyperactivity disorders (ADHD); Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis. The usefulness of α7 nAChR agonists in neurodegeneration is documented in the literature, e.g. in Wang et al., J. biol. Chem. 275, 5626-5632 (2000).
For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.01 to about 100, preferably from about 0.1 to about 50 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 1 to about 500, preferably from about 5 to about 300 mg of an agent of the invention conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
The preferred compound is the stereoisomer of the (l-aza-bicyclo[2.2.2]oct-3-yl)- carbamic acid l-(2-fluorophenyl)-ethyl ester, the succinate of which has a melting
point of 83-84°C and which has an optical rotation of +14.6° (c=l; water, 20°C, 589 nm), which is the compound of Example 61.
In accordance with the foregoing, the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of any condition mentioned above.
The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 150, preferably from about 1 to about 25 mg of a compound according to the invention.
Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above.
In still a further aspect the present invention provides a method for the treatment of any condition mentioned above, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
The following examples illustrate the invention.
Example 1 : (l-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-phenyl-ethyl ester
Imidazole-1-carboxylic acid 1-phenyl-ethyl ester
To a solution of DL-1-phenylethanol 1.21 ml (10.0 mmol) in 10ml tetrahydrofurane, N,N'-carbonyldiimidazole 1.70 g (10.5 mmol) is added. The white suspension is heated up to 50°C and stirred for 40 minutes at this temperature. The reaction mixture is cooled and evaporated. The crude product is purified by flash chromatography (hexane / ethyl acetate 80 / 20) to yield the title product as colorless oil.
(l-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-phenyl-ethyl ester
To a solution of imidazole-1-carboxylic acid 1-phenyl-ethyl ester 0.50 g (2.31 mmol) in 5 ml dimethylformamide, 3-aminoquinuclidine dihydrochloride 0.46 g (2.31 mmol) and sodium carbonate 0.49 g (4.62 mmol) are added. The suspension is heated up to 80 °C and stirred for 18 hours at this temperature. The reaction mixture is then cooled and extracted with water and ethylacetate. The combined organic phases are dried and evaporated. The oily residue is dried, dissolved in ether and acidified with a 4 M hydrochloric acid dioxane solution. The precipitating crystals are filtered, washed with ether and dried to give the title product. Mp = 71 - 72 °C (decomposition).
Example 2: (l-Aza-bicyclo[2.2.21oct-3-yl)-carbamic acid benzyl ester
3-Aminoquinuclidine dihydrochloride 996 mg (5.0 mmol) is added slowly to a stirred suspension of 676 mg (15.5 mmol) sodium hydride (dispersion 55%) in dimethylformamide (15 ml). Thereafter the suspension is stirred for another 90 minutes at room temperature and then carbobenzoxy chloride 0.72 ml (5.1 mmol) is added slowly. After another two hours at room temperature, the suspension is quenched by carefully adding water. The solvent is then evaporated at 70 °C / 16 mbar. The residue is taken up in water and ethyl acetate. The organic phase is separated and the water phase two-times re-extracted with ethyl acetate. The combined organic phase is dried and evaporated to give the crude oily product which is taken up in dioxane and 0.72 ml of a 4M hydrochloric acid is added. The precipitating product is recrystallised from dioxane/ether to give the hydrochloride of the title product. Mp=192 - 193 °C.
Example 3 : (R)-(+)-(l-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzyl ester
Sodium hydride (dispersion 55%) 0.33 g (7.5 mmol) is washed with petrolether and the solvent is removed by separation (decantation). Then, the sodium hydride is carefully suspended in dimethylformamide (12.5 ml). To this suspension (R)-(4-)-3- aminoquinuclidine dihydrochloride 0.50 g (2.5 mmol) is added. The initially exothermic reaction is then stirred at room temperature for one hour and then carbobenzoxy chloride 0.39 ml (2.75 mmol) is added to the reaction mixture within 15 minutes. The again initially exothermic reaction is stirred at room temperature for 90 minutes, then the mixture is poured into 10% brine (NaClΛvater solution) and then four-times extracted with toluene. The combined organic phases are dried and evaporated. The crude oily residue is dissolved in dioxane (5 ml) and 0.31 ml of a 4 M hydrochloric acid is added. The mixture is then stirred at room temperature till the product precipitates. The crystals are filtered, washed with dioxane and ether and dried to give the title product. Mp = 228 - 229 °C. Optical rotation +6.3 ° (c=0.5, water).
Example 4: (S)-(-)-(l-Aza-bicyclo[2.2.21oct-3-yl)-carbamic acid benzyl ester
Sodium hydride (dispersion 55%) 0.33 g (7.5 mmol) is washed with petrolether and the solvent is removed by separation (decantation). Then, the sodium hydride is carefully suspended in dimethylformamide (12.5 ml). To this suspension (S)-(-)-3- aminoquinuclidine dihydrochloride 0.50 g (2.5 mmol) is added. The initially exothermic reaction is then stirred at room temperature for one hour and then carbobenzoxy chloride 0.39 ml (2.75 mmol) is added to the reaction mixture within 15 minutes. The again initially exothermic reaction is stirred at room temperature for 90 minutes then the mixture is poured into 10% brine (NaClΛvater solution) and then four-times extracted with toluene. The combined organic phases are dried and evaporated. The crude oily residue is dissolved in dioxane (5 ml) and 0.31 ml of a 4 M hydrochloric acid is added. The mixture is then stirred at room temperature till the product precipitates. The crystals are filtered, washed with dioxane and ether and dried to give the title product. Mp = 221 - 223 °C. Optical rotation -8.0 ° (c=0.5, water).
Example 5: (l-Aza-bicyclo[2.2.21oct-3-yl)-carbamic acid 4-butyl-benzyl ester
Triethylamine 1.05 ml (7.5 mmol) and 0.80 g di-(N-succinimidyl)carbonate are added to a solution of (4-butyl-phenyl)methanol 0.47 ml (2.75 mmol) in 15 ml dichloromethane. The initial suspension is stirred at room temperature for 45 minutes to become a clear solution. This mixture is added dropwise to a solution of 3- aminoquinuclidine 0.32 g (2.5 mmol) and 0.52 ml (1.5 mmol) triethylamine in 10 ml dichloromethane. The reaction mixture is subsequently stirred for another two hours at room temperature. Afterwards the mixture is washed with 20 ml water. The organic phase is separated, dried and evaporated. The crude product is dissolved in 5 ml dichloromethane and acidified with a saturated solution of hydrochloric acid in ether. By addition of 50 ml ether a white product precipitates. The crystals are filtered, washed with ether and dried to give the title product. Mp = 174 - 175°C (decomposition ) .
The following compounds of formula I wherein n is 2, R and R2 are hydrogen and A is a substituted phenyl group can be prepared in analogy to Examples 1, 2 or 5.
Me = Methyl
* IS: Carbonyl absorption at 1695 cm"1
* * IS: Carbonyl absorption at 1712 cm"1
Example 63: (l-Aza-bicyclo[2.2.21oct-3-yl)-carbamic acid benzo[l,31dioxol-5- ylmethyl ester
Prepared in analogy to example 1, 2 or 5. Mp (hydrochloride) = 186-187°C.
Example 64: (l-Aza-bicyclof2.2.2]oct-3-yl)-carbamic acid benzo[1.31dioxol-4-nitτo- 5-ylmethyl ester
Prepared in analogy to example 1, 2 or 5. Mp (hydrochloride) = 216-218 °C.
Exaπφle 65: (l-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 3,4,5-trimethoxy-benzyl ester
Prepared in analogy to example 1, 2 or 5. Mp (hydrochloride) = 211-212 °C.
Example 66 l-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzo[l,2,5]thiadiazol-5- ylmethyl ester
Prepared in analogy to example 1, 2 or 5. IS: Carbonyl absorption at 1718 cm"1
Claims (10)
- Claims:A compound of formula Iwherein n is 1 or 2, Ri, R2 and R3, independently, are hydrogen or (C1-4)alkyl and A is a group of formulawherein m is 1, 2 or 3, X is O, S, NH or CH2 and R4 and R5, independently, are hydrogen, halogen, hydroxy, ( -4)alkyl, (C1-4)alkoxy, (Cι.4)alkylthio, nitro, trifluoromethyl or phenyl, in free base or acid addition salt form.
- 2. A compound according to claim 1 which is the stereoisomer of the (1-aza- bicyclo[2.2.2]oct-3-yl)-carbamic acid l-(2-fluorophenyl)-ethyl ester, the succinate of which has a melting point of 83-84°C and which has an optical rotation of +14.6° (c=l; water, 20°C, 589 nm), in free base or acid addition salt form.
- 3. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises the step of reacting a compound of formula IIwherein n, R and R2 are as defined in claim 1, with a compound of formula HI wherein R3 and A are as defined in claim 1, and N, N'-carbonyldiimidazole or di(N- succinimidyl)carbonate, and recovering the resulting compound of formula I in free base or acid addition salt form.
- 4. A process for the preparation of a compound of formula I as defined in claim1, or a salt thereof, which comprises the step of reacting a compound of formula IIR, wherein n, Ri and R2 are as defined in claim 1, with a compound of formula IVwherein R3 and A are as defined above, and recovering the resulting compound of formula I in free base or acid addition salt form.
- 5. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
- 6. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of psychotic and neurodegenerative disorders.
- 7. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
- 8. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of psychotic and neurodegenerative disorders.
- 9. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of psychotic and neurodegenerative disorders.
- 10. A method for the treatment of psychotic and neurodegenerative disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0010955.3 | 2000-05-05 | ||
| GBGB0010955.3A GB0010955D0 (en) | 2000-05-05 | 2000-05-05 | Organic compounds |
| PCT/EP2001/005008 WO2001085727A1 (en) | 2000-05-05 | 2001-05-03 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001262257A1 true AU2001262257A1 (en) | 2002-02-07 |
| AU2001262257B2 AU2001262257B2 (en) | 2004-11-04 |
Family
ID=9891092
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6225701A Pending AU6225701A (en) | 2000-05-05 | 2001-05-03 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptoragonists |
| AU2001262257A Ceased AU2001262257B2 (en) | 2000-05-05 | 2001-05-03 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6225701A Pending AU6225701A (en) | 2000-05-05 | 2001-05-03 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptoragonists |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6780861B2 (en) |
| EP (1) | EP1282620B1 (en) |
| JP (1) | JP4898062B2 (en) |
| KR (1) | KR20020093974A (en) |
| CN (1) | CN1167703C (en) |
| AR (1) | AR028073A1 (en) |
| AT (1) | ATE263167T1 (en) |
| AU (2) | AU6225701A (en) |
| BR (1) | BR0110521A (en) |
| CA (1) | CA2407972C (en) |
| CZ (1) | CZ20023622A3 (en) |
| DE (1) | DE60102581T2 (en) |
| DK (1) | DK1282620T3 (en) |
| ES (1) | ES2218418T3 (en) |
| GB (1) | GB0010955D0 (en) |
| HK (1) | HK1054223B (en) |
| HU (1) | HUP0301866A2 (en) |
| IL (1) | IL152417A0 (en) |
| MX (1) | MXPA02010892A (en) |
| NO (1) | NO20025280D0 (en) |
| NZ (1) | NZ522226A (en) |
| PE (1) | PE20020221A1 (en) |
| PL (1) | PL357435A1 (en) |
| PT (1) | PT1282620E (en) |
| RU (1) | RU2002131886A (en) |
| SK (1) | SK15612002A3 (en) |
| TR (1) | TR200401007T4 (en) |
| WO (1) | WO2001085727A1 (en) |
| ZA (1) | ZA200208969B (en) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6262265A (en) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | Automatic inspection/repair system for condenser |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| PE20021019A1 (en) * | 2001-04-19 | 2002-11-13 | Upjohn Co | SUBSTITUTED AZABYCLE GROUPS |
| EP1448546A4 (en) * | 2001-11-02 | 2005-02-02 | Searle Llc | Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
| DE10164139A1 (en) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-heteroaryl carboxamides |
| US6852716B2 (en) * | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
| BR0307782A (en) | 2002-02-19 | 2005-01-04 | Upjohn Co | Azabicycle compounds for the treatment of disease |
| DE10234424A1 (en) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophene, benzofuran and indoleureas |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| EP1581223B2 (en) | 2002-12-06 | 2016-05-25 | The Feinstein Institute for Medical Research | Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| WO2004085433A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| KR20060120694A (en) | 2003-12-22 | 2006-11-27 | 메모리 파마슈티칼스 코포레이션 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| US20050170360A1 (en) * | 2004-01-30 | 2005-08-04 | Papke Roger L. | Variant neuronal nicotinic alpha-7 receptor and methods of use |
| WO2005075479A1 (en) * | 2004-02-04 | 2005-08-18 | Neurosearch A/S | Dimeric azacyclic compounds and their use |
| US20050234095A1 (en) | 2004-03-25 | 2005-10-20 | Wenge Xie | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| WO2006001894A1 (en) * | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| WO2005111038A2 (en) * | 2004-05-07 | 2005-11-24 | Memory Pharmaceuticals Corporation | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| AR049401A1 (en) | 2004-06-18 | 2006-07-26 | Novartis Ag | AZA-BICICLONONANS |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| RU2418797C2 (en) | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | LIGANDS OF NICOTINE RECEPTOR α, THEIR OBTAINING AND APPLICATION |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| SA08290475B1 (en) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof |
| LT2889033T (en) | 2008-11-19 | 2018-07-10 | Forum Pharmaceuticals Inc. | Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| WO2010132423A1 (en) * | 2009-05-11 | 2010-11-18 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
| WO2011009890A2 (en) | 2009-07-23 | 2011-01-27 | Novartis Ag | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
| JO3250B1 (en) | 2009-09-22 | 2018-09-16 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| JP5633405B2 (en) * | 2010-02-18 | 2014-12-03 | Jsr株式会社 | Novel compound, radiation-sensitive composition and cured film |
| JP5852094B2 (en) * | 2010-03-26 | 2016-02-03 | コーニング インコーポレイテッド | Low nonlinear long distance optical communication system |
| PL3029039T3 (en) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate |
| CA2808797A1 (en) | 2010-07-26 | 2012-02-02 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
| CN103442701A (en) * | 2011-01-27 | 2013-12-11 | 诺瓦提斯公司 | Use of nicotinic acetylcholine receptor alpha 7 activators |
| JP6031458B2 (en) * | 2011-03-18 | 2016-11-24 | ノバルティス アーゲー | Combination of alpha7 nicotinic acetylcholine receptor activator and mGluR5 antagonist for use in dopamine-induced dyskinesia in Parkinson's disease |
| PT2685986T (en) * | 2011-03-18 | 2020-03-05 | Genzyme Corp | Glucosylceramide synthase inhibitors |
| EP2702041A1 (en) * | 2011-04-29 | 2014-03-05 | Chiesi Farmaceutici S.p.A. | Alkaloid ester and carbamate derivatives and medicinal compositions thereof |
| JO3766B1 (en) | 2011-10-20 | 2021-01-31 | Novartis Ag | alpha 7 nicotinic acetylcholine receptor activator |
| EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | Methods of maintaining, treating or improving cognitive function |
| MA37975B2 (en) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Glucosylceramide synthase inhibitors |
| JP6114951B2 (en) | 2012-12-11 | 2017-04-19 | ノバルティス アーゲー | Biomarkers that predict responsiveness to treatment with alpha 7 nicotinic acetylcholine receptor activators |
| JP6137336B2 (en) * | 2013-01-15 | 2017-05-31 | ノバルティス アーゲー | Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy |
| CN105263495B (en) | 2013-01-15 | 2019-05-14 | 诺华有限公司 | The application of alpha 7 nicotinic acetylcholine receptors agonist |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| WO2014111837A1 (en) | 2013-01-15 | 2014-07-24 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| CA3166777A1 (en) | 2020-02-03 | 2021-08-12 | Nigel Patrick Somerville CRAWFORD | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| TW202220648A (en) | 2020-07-24 | 2022-06-01 | 美商健臻公司 | Pharmaceutical compositions comprising venglustat |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| WO1995006635A1 (en) * | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| AU3470495A (en) | 1994-09-14 | 1996-03-29 | H. Lundbeck A/S | Carbamoyloxy amine compounds |
| GB9525261D0 (en) | 1995-12-11 | 1996-02-07 | Bayer Ag | Carbamic acid derivatives |
| GB9526560D0 (en) * | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| SE9600683D0 (en) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| WO1997046557A1 (en) * | 1996-06-05 | 1997-12-11 | Wolfgang Lindner | Cinchonan based chiral selectors for separation of stereoisomers |
| US6624173B1 (en) * | 1997-06-30 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions for treating and/or preventing CNS disorders |
| US6525065B1 (en) * | 1997-06-30 | 2003-02-25 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| US5988429A (en) * | 1997-10-14 | 1999-11-23 | Pharmadesign, Inc. | Blister pack pill dispenser |
| EP1217001B1 (en) * | 1999-09-28 | 2005-12-07 | Eisai Co., Ltd. | Quinuclidine compounds and drugs containing the same as the active ingredient |
| AU2001282874A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| GB0109871D0 (en) * | 2001-04-20 | 2001-06-13 | Glaxo Group Ltd | Metering method for particulate material |
-
2000
- 2000-05-05 GB GBGB0010955.3A patent/GB0010955D0/en not_active Ceased
-
2001
- 2001-05-03 IL IL15241701A patent/IL152417A0/en unknown
- 2001-05-03 CN CNB01808821XA patent/CN1167703C/en not_active Expired - Fee Related
- 2001-05-03 US US10/258,920 patent/US6780861B2/en not_active Expired - Fee Related
- 2001-05-03 ES ES01936319T patent/ES2218418T3/en not_active Expired - Lifetime
- 2001-05-03 NZ NZ522226A patent/NZ522226A/en unknown
- 2001-05-03 PL PL01357435A patent/PL357435A1/en not_active Application Discontinuation
- 2001-05-03 AR ARP010102089A patent/AR028073A1/en not_active Application Discontinuation
- 2001-05-03 KR KR1020027014760A patent/KR20020093974A/en not_active Application Discontinuation
- 2001-05-03 EP EP01936319A patent/EP1282620B1/en not_active Expired - Lifetime
- 2001-05-03 PE PE2001000399A patent/PE20020221A1/en not_active Application Discontinuation
- 2001-05-03 AT AT01936319T patent/ATE263167T1/en active
- 2001-05-03 HU HU0301866A patent/HUP0301866A2/en unknown
- 2001-05-03 BR BR0110521-3A patent/BR0110521A/en not_active Application Discontinuation
- 2001-05-03 RU RU2002131886/04A patent/RU2002131886A/en not_active Application Discontinuation
- 2001-05-03 TR TR2004/01007T patent/TR200401007T4/en unknown
- 2001-05-03 CZ CZ20023622A patent/CZ20023622A3/en unknown
- 2001-05-03 CA CA002407972A patent/CA2407972C/en not_active Expired - Fee Related
- 2001-05-03 PT PT01936319T patent/PT1282620E/en unknown
- 2001-05-03 WO PCT/EP2001/005008 patent/WO2001085727A1/en not_active Application Discontinuation
- 2001-05-03 MX MXPA02010892A patent/MXPA02010892A/en unknown
- 2001-05-03 AU AU6225701A patent/AU6225701A/en active Pending
- 2001-05-03 DE DE60102581T patent/DE60102581T2/en not_active Expired - Lifetime
- 2001-05-03 JP JP2001582328A patent/JP4898062B2/en not_active Expired - Fee Related
- 2001-05-03 SK SK1561-2002A patent/SK15612002A3/en unknown
- 2001-05-03 AU AU2001262257A patent/AU2001262257B2/en not_active Ceased
- 2001-05-03 DK DK01936319T patent/DK1282620T3/en active
-
2002
- 2002-11-04 NO NO20025280A patent/NO20025280D0/en not_active Application Discontinuation
- 2002-11-05 ZA ZA200208969A patent/ZA200208969B/en unknown
-
2003
- 2003-07-07 HK HK03104830.3A patent/HK1054223B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4898062B2 (en) | Azabicyclic carbamate and its use as an alpha-7 nicotinic acetylcholine receptor agonist | |
| AU2001262257A1 (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | |
| KR100808324B1 (en) | Aza-bicycloalkyl Ethers and Their Use as Alpha7-nAChR Agonists | |
| US5998429A (en) | Azabicyclic esters of carbamic acids useful in therapy | |
| JP3939246B2 (en) | Indoloquinazolinones | |
| PL163580B1 (en) | Method for manufacturing derivatives of 2-piperidine alkohol-1 | |
| JPH02138266A (en) | 6-phenyl-3-(piperazinylalkyl)-2,4(1h,3h)-pyrimidine dione derivative | |
| JPH0747585B2 (en) | Isoxazole derivative | |
| JP6808088B2 (en) | Fluoropiperidine compounds as pure 5-HT6 receptor antagonists | |
| EP0457243A1 (en) | Novel tricyclic compounds | |
| US7683075B2 (en) | Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof | |
| CA1314885C (en) | Tricyclic derivatives which are agonists of cholinergic receptors, and drugs in which they are present | |
| JPH07309867A (en) | Tryptamine derivative and its use |